Previous 10 | Next 10 |
Alnylam Pharmaceuticals (ALNY) announces positive early results from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). Among 24 patients in ILLUMINATE-A who had been treated with lumasiran for 12 months, 46% (11/...
– OXLUMO Demonstrated Improvements in Nephrocalcinosis in Patients with Primary Hyperoxaluria Type 1 After 12 Months of Treatment – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results o...
Image source: The Motley Fool. Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Q1 2021 Earnings Call Apr 29, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transc...
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2021 Earnings Conference Call April 29, 2021 08:30 AM ET Company Participants Christine Lindenboom - Senior Vice President, Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Tolga Tanguler - Chief Commercial Off...
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Alnylam Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
Alnylam Pharmaceuticals (ALNY) posted first-quarter net loss that missed Wall Street estimates, and reiterated its financial forecast for the year.The company reported adjusted quarterly net loss of $1.64 per share, missing analysts' average estimate by 24 cents.However, Alnylam's first-...
− Achieved First Quarter 2021 Combined Net Product Revenues of $136 Million for ONPATTRO ® , GIVLAARI ® , and OXLUMO ® – − Advanced Vutrisiran toward Market with Positive Results from HELIOS-A Phase 3 Study and Submission of New ...
Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q1 earnings results on Thursday, April 29th, before market open.The consensus EPS Estimate is -$1.37 (+9.9% Y/Y) and the consensus Revenue Estimate is $169.06M (+69.9% Y/Y).Over the last 2 years, ALNY has beaten EPS estimates 25% ...
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this event. For further details see: Alnylam Pharmaceuticals (ALNY) Updates On 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Slideshow
Alnylam Therapeutics (ALNY) has submitted an NDA to the FDA for its RNAi candidate vutrisiran for hereditary ATTR ("hATTR") amyloidosis with polyneuropathy.The application is supported by data from the phase 3 HELIOS-A trial, which met its primary and secondary endpoints.At 9 months...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...